TWIN TIERS, N.Y. (WENY) -- Mounjaro, also known as Tirzepatide, is a new Type 2 Diabetes treatment, approved by the FDA nearly five months ago. This medication is showing favorable results by decreasing glucose levels, according to Dr. Ahmet Can, an endocrinologist at the Arnot Ogden Medical Center.

Dr. Can says Mounjaro helps the pancreas secrete its own insulin in diabetes patients. With this new medicine, patients can manage their diabetes in a better way, according to Dr. Can. Mounjaro also decreases hemoglobin C1 level in patients as well, according to the U.S Food and Drug Administration.

Through trials, Dr. Can added, this Mounjaro also drops blood sugar levels within three months. This new medicine has changed the medical world's approach to diabetes with staggering results. Dr. Can said there is another new-found benefit to this medication: weight loss.

“The most spectacular thing about this medication is the degree of weight loss,” he said. “They lost about, like, 70 to 80 pounds...which is a lot but their starting weight was much higher.”

Dr. Can said, through trial results, patients lose 27 pounds on average within the first few months of using Mounjaro. Some people lose 40 to 50 pounds; other times, people can lose 70 to 80 pounds.

Dr. Can said it takes about a month for patients to see results in regard to weight loss. He added, although this is an exciting effect of the new medicine, Type 2 Diabetes patients should prioritize a healthy diet and daily exercise, as well.